Results 31 to 40 of about 341,067 (311)
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
Journal of Market Access & Health Policy, 2017 Introduction: Health technology assessment (HTA) in Poland supports reimbursement decisions via the Polish HTA Agency (AOTMiT), whose guidelines were updated in 2016.
Krzysztof Lach +3 more
doaj +1 more source
Comparison of Cardiovascular Medicines Prices in Four European Countries
Frontiers in Public Health, 2020 The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-
Zornitsa Mitkova +8 more
doaj +1 more source
Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? [PDF]
European Economic Review, 2007 We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation.
Kurt R. Brekke +2 more
openaire +5 more sources
Profitability effects of financial globalization in an emerging market banking industry: insights into Turkey [PDF]
Zbornik radova Ekonomskog fakulteta u Rijeci : časopis za ekonomsku teoriju i praksu, 2019 The massive financial liberalization followed by accelerating financial globalization leaded to significant structural changes in the financial sector.
Ece C. Akdoğan, Ekin Ayşe Özşuca
doaj +1 more source
Journal of Financial Economics, 2009 We examine how collateral affects the cost of debt capital. Theories based on borrower moral hazard and limited pledgeable income predict that collateral increases the availability of credit and reduces its price. Testing these theories is complicated by the very selection problem which they imply: creditors will demand collateral precisely from those ...
Benmelech, Efraim, Bergman, Nittai
openaire +4 more sources
Pricing of Consumer Innovations [PDF]
, 2022 Consumers are an important source of innovation. They primarily innovate out of non-monetary motivations, such as use interest, learning and social rewards.
Ebbing, Tobias
core +1 more source
A comparative study of orphan drug prices in Europe
Journal of Market Access & Health Policy, 2017 Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK.
Katherine Eve Young +3 more
doaj +1 more source
Distributional Impacts of Carbon Pricing on Households
, 2020 Carbon pricing policies that are aligned with the Paris Agreement objectives will have positive and negative socio-economic impacts on society. Impacts of unabated climate change are expected to disrupt economic
Carbon Pricing Leadership Coalition
core +1 more source
A resource-advantage perspective on pricing: shifting the focus from ends to means-end in pricing research? [PDF]
, 2013 This paper contributes to a long-lasting debate between practitioners who argue that academia is unable to understand what pricing is all about and academics who criticize practitioner pricing approaches for lacking rigor or rationality.
Roper, Angela +2 more
core +1 more source
GMS German Medical Science, 2022 Background: Horizon scanning aims to systematically identify upcoming health technologies and thus allows policy-makers to be better prepared for the entry of new medicines with possibly high price tags into the national health system.
Vogler, Sabine
doaj +1 more source